請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50230
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳小梨(Show-Li Chen) | |
dc.contributor.author | Ping Fan | en |
dc.contributor.author | 范萍 | zh_TW |
dc.date.accessioned | 2021-06-15T12:33:16Z | - |
dc.date.available | 2021-08-26 | |
dc.date.copyright | 2016-08-26 | |
dc.date.issued | 2016 | |
dc.date.submitted | 2016-08-02 | |
dc.identifier.citation | Aarnisalo P, Palvimo JJ, Jänne OA. (1998) CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci U S A. 95: 2122-2127.
Abate-Shen C, Shen MM. (2000) Molecular genetics of prostate cancer. Genes Dev.14: 2410-2434. Aranda A, Pascual A. (2001) Nuclear hormone receptors and gene expression. Physiol Rev. 81: 1269-1304. Barakat BM, Wang QE, Han C, Milum K, Yin DT, Zhao Q, Wani G, Arafa el-SA, El-Mahdy MA, Wani AA. (2010) Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis. Int J Cancer. 127: 977-988. Barckhausen C, Roos WP, Naumann SC, Kaina B. (2014) Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair. Oncogene. 33: 1964-19674. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, Garraway LA, Rubin MA, Demichelis F (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med. 22:298-305. Blessing AM, Ganesan S, Rajapakshe K, Ying Sung Y, Reddy Bollu L, Shi Y, Cheung E, Coarfa C, Chang JT, McDonnell DP, Frigo DE (2015) Identification of a Novel Coregulator, SH3YL1, That Interacts With the Androgen Receptor N-Terminus. Mol Endocrinol. 29: 1426-1439. Bonkhoff H, Fixemer T, Remberger K. (1998) Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate. 34: 251-258. Bosch DG, Boonstra FN, de Leeuw N, Pfundt R, Nillesen WM, de Ligt J, Gilissen C, Jhangiani S, Lupski JR, Cremers FP, de Vries BB. (2016) Novel genetic causes for cerebral visual impairment. Eur J Hum Genet. 24: 660-665. Brady ME, Ozanne DM, Gaughan L, Waite I, Cook S, Neal DE, Robson CN. (1999) Tip60 is a nuclear hormone receptor coactivator. J Biol Chem. 274: 17599-17604. Burnstein KL (2005) Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. J Cell Biochem. 95: 657-669. Cancer Genome Atlas Research Network. (2015) The Molecular Taxonomy of Primary Prostate Cancer. Cell. 163: 1011-25. Chang SW, Lu PY, Guo JH, Tsai TC, Tsao YP, Chen SL. (2012) NRIP enhances HPV gene expression via interaction with either GR or E2. Virology. 423: 38-48. Chang SW, Su CH, Chen HH, Huang CW, Tsao LP, Tsao YP, Chen SL. (2012) DDB2 is a novel AR interacting protein and mediates AR ubiquitination/degradation. Int J Biochem Cell Biol. 44: 1952-1961. Chen HH, Chen WP, Yan WL, Huang YC, Chang SW, Fu WM, Su MJ, Yu IS, Tsai TC, Yan YT, Tsao YP, Chen SL. (2015) NRIP is newly identified as a Z-disc protein, activating calmodulin signaling for skeletal muscle contraction and regeneration. J Cell Sci. 128: 4196-4209. Chen PH, Tsao YP, Wang CC, Chen SL. (2008) Nuclear receptor interaction protein, a coactivator of androgen receptors (AR), is regulated by AR and Sp1 to feed forward and activate its own gene expression through AR protein stability. Nucleic Acids Res. 36: 51-66. Culig Z, Santer FR. (2014) Androgen receptor signaling in prostate cancer. Cancer Metastasis Rev. 33: 413-427. Dema A, Borda A, Lazăr E, Lăzureanu C, Tăban S, Anderco D, Cornianu M, Mureşan A, Herman D, Loghin A, Cornea R, Faur A. (2010) Prostate lesions with cribriform / pseudocribriform pattern. Rom J Morphol Embryol. 51: 413-425. Ennen M, Klotz R, Touche N, Pinel S, Barbieux C, Besancenot V, Brunner E, Thiebaut D, Jung AC, Ledrappier S, Domenjoud L, Abecassis J, Plénat F, Grandemange S, Becuwe P. (2013) DDB2: a novel regulator of NF-κB and breast tumor invasion. Cancer Res. 73: 5040-5052. Ertel A, Verghese A, Byers SW, Ochs M, Tozeren A. (2006) Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol Cancer. 5: 55. Fleischmann A, Rocha C, Schobinger S, Seiler R, Wiese B, Thalmann GN. (2011) Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. Prostate. 71: 453-460. Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C. (1999) Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem. 274: 8316-8321. Han C, Zhao R, Liu X, Srivastava A, Gong L, Mao H, Qu M, Zharo W, Yu J, Wrang QE. (2014) DDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer. Mol Cancer Res. 12: 784-794. Han CP, Lee MY, Tzeng SL, Yao CC, Wang PH, Cheng YW, Chen SL, Wu TS, Tyan YS, Kok LF. (2008) Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization. J Exp Clin Cancer Res. 27: 25. Hayward SW, Baskin LS, Haughney PC, Cunha AR, Foster BA, Dahiya R, Prins GS, Cunha GR. (1996) Epithelial development in the rat ventral prostate, anterior prostate and seminal vesicle. Acta Anat (Basel) 155: 81-93. He YJ, McCall CM, Hu J, Zeng Y, Xiong Y. (2006) DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev. 20: 2949-2954. Heinlein CA, Chang C. (2004) Androgen receptor in prostate cancer. Endocr Rev. 25: 276-308. Hu Z, Shao M, Yuan J, Xu L, Wang F, Wang Y, Yuan W, Qian J, Ma H, Wang Y, Liu H, Chen W, Yang L, Jin G, Huo X, Chen F, Jin L, Wei Q, Huang W, Lu D, Wu T, Shen H. (2006) Polymorphisms in DNA damage binding protein 2 (DDB2) and susceptibility of primary lung cancer in the Chinese: a case-control study. Carcinogenesis. 27: 1475-1480. Humphrey PA. (2004) Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol. 17: 292-306. Humphrey PA. (2012) Histological variants of prostatic carcinoma and their significance. Histopathology. 60: 59-74. Itoh T, Cado D, Kamide R, Linn S. (2004) DDB2 gene disruption leads to skin tumors and resistance to apoptosis after exposure to ultraviolet light but not a chemical carcinogen. Proc Natl Acad Sci U S A. 101: 2052-2057. Itoh T, Iwashita S, Cohen MB, Meyerholz DK, Linn S. (2007) Ddb2 is a haploinsufficient tumor suppressor and controls spontaneous germ cell apoptosis. Hum Mol Genet. 16: 1578-1586. Jin J, Arias EE, Chen J, Harper JW, Walter JC. (2006) A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell. 23: 709-721. Kumar A, Coleman I, Morrissey C, Zhang X, True LD, Gulati R, Etzioni R, Bolouri H, Montgomery B, White T, Lucas JM, Brown LG, Dumpit RF, DeSarkar N, Higano C, Yu EY, Coleman R, Schultz N, Fang M, Lange PH, Shendure J, Vessella RL, Nelson PS (2016) Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med. 22: 369-378. Kuo PC, Huang CW, Lee CI, Chang HW, Hsieh SW, Chung YP, Lee MS, Huang CS, Tsao LP, Tsao YP, Chen SL. (2015) BCAS2 promotes prostate cancer cells proliferation by enhancing AR mRNA transcription and protein stability. Br J Cancer. 112: 391-402. Latour M, Amin MB, Billis A, Egevad L, Grignon DJ, Humphrey PA, Reuter VE, Sakr WA, Srigley JR, Wheeler TM, Yang XJ, Epstein JI. (2008) Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol. 32: 1532-1539. Lee SO, Tian J, Huang CK, Ma Z, Lai KP, Hsiao H, Jiang M, Yeh S, Chang C. (2012) Suppressor role of androgen receptor in proliferation of prostate basal epithelial and progenitor cells. J Endocrinol. 213: 173-82. Li B, Lu W, Chen Z. (2014) Regulation of Androgen Receptor by E3 Ubiquitin Ligases: for More or Less. Receptors Clin Investig. 1. Lin HK, Wang L, Hu YC, Altuwaijri S, Chang C. (2002) Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J 21: 4037-4048. Lonergan PE, Tindall DJ. (2011) Androgen receptor signaling in prostate cancer development and progression. J Carcinog 10: 20. Lyons LS, Burnstein KL. (2006) Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Mol Endocrinol. 20: 1061-1072. Ma H, Hong H, Huang SM, Irvine RA, Webb P, Kushner PJ, Coetzee GA, Stallcup MR. (1999) Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins. Mol Cell Biol. 19: 6164-6173. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. (1995) The nuclear receptor superfamily: the second decade. Cell 83: 835-839. Matsuda N, Azuma K, Saijo M, Iemura S, Hioki Y, Natsume T, Chiba T, Tanaka K, Tanaka K. (2005) DDB2, the xeroderma pigmentosum group E gene product, is directly ubiquitylated by Cullin 4A-based ubiquitin ligase complex. DNA Repair (Amst). 4: 537-545. Minig V, Kattan Z, van Beeumen J, Brunner E, Becuwe P. (2009) Identification of DDB2 protein as a transcriptional regulator of constitutive SOD2 gene expression in human breast cancer cells. J Biol Chem. 284: 14165-14176. Mohler JL. (2008) A role for the androgen-receptor in clinically localized and advanced prostate cancer. Best Pract Res Clin Endocrinol Metab. 22: 357-372. Murata S, Minami Y, Minami M, Chiba T, Tanaka K. (2001) CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep 2: 1133-1138. Nakano K, Miki Y, Hata S, Ebata A, Takagi K, McNamara KM, Sakurai M, Masuda M, Hirakawa H, Ishida T, Suzuki T, Ohuchi N, Sasano H. (2013) Identification of androgen-responsive microRNAs and androgen-related genes in breast cancer. Anticancer Res. 33: 4811-4819. Niu Y, Altuwaijri S, Lai KP, Wu CT, Ricke WA, Messing EM, Yao J, Yeh S, Chang C. (2008) Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci U S A. 105: 12182-12187. Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C. (2010) Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene. 29: 3593-3604. Oh KS, Emmert S, Tamura D, DiGiovanna JJ, Kraemer KH. (2011) Multiple skin cancers in adults with mutations in the XP-E (DDB2) DNA repair gene. J Invest Dermatol. 131: 785-788. Packer JR1, Maitland NJ2. (2016) The molecular and cellular origin of human prostate cancer. Biochim Biophys Acta. 1863: 1238-1260. Peacock SO, Fahrenholtz CD, Burnstein KL. (2012) Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Mol Endocrinol. 26: 1967-1979. Poukka H, Aarnisalo P, Karvonen U, Palvimo JJ, Jänne OA. (1999) Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J Biol Chem. 274: 19441-19446. Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA. (2013) The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity. Cancer Cell 23: 332-346. Qiao S, Guo W, Liao L, Wang L, Wang Z, Zhang R, Xu D, Zhang Y, Pan Y, Wang Z, Chen Y. (2015) DDB2 is involved in ubiquitination and degradation of PAQR3 and regulates tumorigenesis of gastric cancer cells. Biochem J. 469: 469-480. Qiu YQ, Leuschner I, Braun PM. (2008) Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review. Asian J Androl. 10: 855-863. Riou P, Saffroy R, Comoy J, Gross-Goupil M, Thiéry JP, Emile JF, Azoulay D, Piatier-Tonneau D, Lemoine A, Debuire B. (2002) Investigation in liver tissues and cell lines of the transcription of 13 genes mapping to the 16q24 region that are frequently deleted in hepatocellular carcinoma. Clin Cancer Res. 8: 3178-3186. Rizzardi AE, Johnson AT, Vogel RI, Pambuccian SE, Henriksen J, Skubitz AP, Metzger GJ, Schmechel SC. (2012) Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol. 7: 42. Robinson B, Magi-Galluzzi C, Zhou M. (2012) Intraductal carcinoma of the prostate. Arch Pathol Lab Med. 136: 418-425. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM (2015) Integrative clinical genomics of advanced prostate cancer. Cell. 161:1215-1228. Rochette-Egly C. (2003) Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cell Signal. 15: 355-366. Roy N, Bommi PV, Bhat UG, Bhattacharjee S, Elangovan I, Li J, Patra KC, Kopanja D, Blunier A, Benyra R, Bagchi S, Raychaudhuri P. (2013) DDB2 suppresses epithelial-to-mesenchymal transition in colon cancer. Cancer Res. 73: 3771-3782. Simanainen U, Allan CM, Lim P, McPherson S, Jimenez M, Zajac JD, Davey RA, Handelsman DJ. (2007) Disruption of prostate epithelial androgen receptor impedes prostate lobe-specific growth and function. Endocrinology 148: 2264-2272. Singh M, Jha R, Melamed J, Shapiro E, Hayward SW, Lee P. (2014) Stromal androgen receptor in prostate development and cancer. Am J Pathol. 184: 2598-2607. Stallcup MR, Chen D, Koh SS, Ma H, Lee YH, Li H, Schurter BT, Aswad DW. (2000) Co-operation between protein-acetylating and protein-methylating co-activators in transcriptional activation. Biochem Soc Trans 28: 415-418. Stoyanova T, Roy N, Bhattacharjee S, Kopanja D, Valli T, Bagchi S, Raychaudhuri P. (2012) p21 cooperates with DDB2 protein in suppression of ultraviolet ray-induced skin malignancies. J Biol Chem. 287: 3019-3028. Tan MH, Li J, Xu HE, Melcher K, Yong EL. (2015) Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 36: 3-23. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11-22. Tsai TC, Lee YL, Hsiao WC, Tsao YP, Chen SL. (2005) NRIP, a novel nuclear receptor interaction protein, enhances the transcriptional activity of nuclear receptors. J Biol Chem. 280: 20000-20009. van de Wijngaart DJ, Dubbink HJ, van Royen ME, Trapman J, Jenster G. (2012) Androgen receptor coregulators: recruitment via the coactivator binding groove. Mol Cell Endocrinol. 352: 57-69. Vatten LJ, Ursin G, Ross RK, Stanczyk FZ, Lobo RA, Harvei S, Jellum E. (1997) Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev. 6: 967-969. Wang C, Sun H, Zou R, Zhou T, Wang S, Sun S, Tong C, Luo H, Li Y, Li Z, Wang E, Chen Y, Cao L, Li F, Zhao Y. (2015) MDC1 functionally identified as an androgen receptor co-activator participates in suppression of prostate cancer. Nucleic Acids Res. 43: 4893-4908. Wilhelm D, Koopman P. (2006) The makings of maleness: towards an integrated view of male sexual development. Nat Rev Genet. 7: 620-631. Xu K, Shimelis H, Linn DE, Jiang R, Yang X, Sun F, Guo Z, Chen H, Li W, Chen H, Kong X, Melamed J, Fang S, Xiao Z, Veenstra TD, Qiu Y. (2009) Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell 15: 270-282. Yeh S, Chang C. (1996) Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci U S A. 93: 5517-5521. Yeh S, Niu Y, Miyamoto H, Chang T, Chang C. (2009) Differential Roles of Androgen Receptor in Prostate Development and Cancer Progression. Androgen Action in Prostate Cancer: 73-89 Yoon T, Chakrabortty A, Franks R, Valli T, Kiyokawa H, Raychaudhuri P. (2005) Tumor-prone phenotype of the DDB2-deficient mice. Oncogene. 24: 469-478. Zhao R, Cui T, Han C, Zhang X, He J, Srivastava AK, Yu J, Wani AA, Wang QE. (2015) DDB2 modulates TGF-β signal transduction in human ovarian cancer cells by downregulating NEDD4L. Nucleic Acids Res. 43: 7838-7849. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/50230 | - |
dc.description.abstract | 之前我們實驗室發現新的基因核受體交互作用蛋白(nuclear receptor interaction protein, NRIP),又名IQWD1。另外也屬於 DDB1 和 CUL4 相關因子(DCAF), 所以又名 DCAF6。 NRIP含有7個WD40 domain,是類固醇受體(雄激素受體和糖皮質激素受體)的共活化劑。雄激素受體 (androgen receptors; AR)曾被報導會影響攝護腺的發育,而我們先前的研究也發現NRIP可以穩定AR蛋白; 而最近的研究發現8周大的NRIP基因剃除小鼠的前側攝護腺發育較野生型遲緩,但是腹側和背外側攝護腺的發育和野生型比較則沒有差別。野生型小鼠的前側攝護腺的AR表現量為三者中最低,NRIP基因剃除小鼠前側攝護腺的AR表現量又比野生型小鼠的前側攝護腺更低。這表示NRIP 也許會和AR交互作用,進而調控前側攝護腺的發育而非腹側和背外側攝護腺。另一方面,在前側攝護腺的AR 蛋白比在腹側和背外側攝護腺少,因此在8周NRIP 基因剃除小鼠前側攝護腺的AR蛋白不足以超越小鼠前攝護腺生長所需的閾值。
另外,我們發現受損DNA結合蛋白2 (damge-specific DNA binding protein 2; DDB2)又名p48、XPE,會調控AR的泛素化和降解。像NRIP一樣,DDB2也屬於DDB1 和 CUL4 相關因子(DCAF)並含有WD40 domain。DDB2會和DDB1-CUL4E3 ligase結合並泛素化目標蛋白AR,最後透過蛋白酶體降解AR。目前我們發現NRIP會跟DDB2競爭和AR的結合,防止DDB2-DDB1-CUL4 E3 ligase複合體降解AR蛋白。 因此為了更進一步探討在攝護腺癌病人中NRIP, DDB2和AR的表現,我們使用了免疫組織化學染色實驗。Pearson's 卡方檢定結果顯示,和非癌化的對照組相比,在攝護腺癌化病人中,NRIP的表現量顯著增加,而DDB2的表現量則降低(n=260; 樣本來源:台大醫院和US Biomax Inc.)。在攝護腺癌化病人中,AR的表現量也是顯著增加。NRIP和AR的表現呈現正相關,進一步支持我們在in vitro 的實驗:NRIP會穩定AR蛋白。然而DDB2和AR的表現也呈現正相關,這可以解釋為在AR表現高的病人中,DNA修補機制會被啟動,因此增加DDB2表現。另一方面,NRIP 和 DDB2 的蛋白質表現也是正相關,可能是NRIP表現高的病人,DNA修補機制會被啟動,因此增加DDB2表現。NRIP、DDB2和AR的蛋白質表現也沒有顯著的差異,但是當我們將NRIP表現量高、AR高和DDB2低的檢體分為一組,而其他七種組合為一組,依照癌症型態分為篩狀(cribriform) 和非篩狀(non-cribriform),並用卡方檢定計算p值。結果顯示在相同位點的篩狀病灶顯著觀察到NRIP表現量很高、AR很高而DDB2低 (勝負比: 2.64; 95%信賴區間: 1.02~6.59)。有趣的是,當我們將NRIP表現量高、AR高和DDB2低的檢體分為一組,而其他三種DDB2表現皆低的組合為一組,用卡方檢定計算的p值比前一個更顯著 (勝負比: 4.82; 95%信賴區間: 1.48~16.9) 這表示在DDB2表現低的篩狀攝護腺病灶NRIP和AR表現量高。因此在DDB2表現低時NRIP會保護AR。至於DDB2表現高時NRIP是否會保護AR不被DDB2 透過Cul4-DDB1 E3 ligase複合體降解還未知。 | zh_TW |
dc.description.abstract | The gene, nuclear receptor interaction protein (NRIP, also named IQWD1) was found in our lab. NRIP is in DDB1 and CUL4-associated factors (DCAF) family, so it's also known as DCAF6. NRIP contains seven WD40 repeats and functions as the coactivator of steroid receptors (androgen receptor and glucocorticoid receptor). Androgen receptor (AR) reportedly participates in the development of prostate. Currently, NRIP can stabilize AR protein. From NRIP knock out mice (NRIP KO), we found that the anterior prostate (AP) development of 8-week NRIP KO mouse was slower than that of wild type (WT), but the development of lateral prostate (LP) and dorsal-lateral prostate (DLP) did not differ for their development as wild type. And the expression of AR of AP was the lowest among the three prostate lobes in WT mice; and AR expression in AP of NRIP KO mouse was also lower than the counterpart of WT. These imply that NRIP may regulate AR and then regulate the development of anterior prostate but not LP and DLP. On the other hand, AR protein in AP was less than that in LP or DLP. Hence, AR protein in AP of 8-week NRIP KO mouse was not enough to cross the threshold of the AP development in mouse. In addition, we found that damage-specific DNA binding protein 2 (DDB2, also named p48 and XPE) interacts with AR and mediates its ubiquitination and degradation. DDB2, like NRIP, is a DCAF containing protein. DDB2 binding to DDB1-CUL4 E3 ligase can ubiquitinate AR for proteasomal degradation. Currently, we found that NRIP competed with DDB2 for AR binding to avoid DDB2-DDB1-CUL4 E3 ligase complex degrading AR protein. Hence, in this study to further investigate NRIP, DDB2, and AR expression in prostate cancer clinical patients, we performed immunohistochemistry (IHC) assay. The results revealed that NRIP protein expression was significantly increased in human prostate cancer patients, while DDB2 expression was decreased in compared to non-neoplastic control by Pearson's chi-square (n=260, from NTUH and US Biomax Inc.). As to expression of AR, it was significantly increased in prostate cancer patients compared with non-neoplastic controls by Pearson's chi-square analysis. When analyzing the correlation between NRIP and AR, there was positive correlation between NRIP and AR. It further supports our in vitro demonstration of NRIP-stabilizing AR protein. However, the correlation between DDB2 and AR also revealed positive correlation; it can explain AR high expression patients; that may induce DNA repair mechanism that drives DDB2 expression for repair. On the other hand, the relation between NRIP and DDB2 also exhibited positive correlation; the explanation is that NRIP high expression patients may stimulate DNA repair mechanism that drives DDB2 expression for repair. Moreover, to analyze NRIP, DDB2 and AR, there was no correlation among these three proteins’ expression in human prostate cancer samples. But when we further categorized high NRIP and high AR expression along with low DDB2 expression as a group, and the other seven combinations as one group; and analyzed p value between these two groups with cribriform and non-cribriform prostate cancer by Chi-square assay. The results showed the high NRIP and AR and low DDB2 expression at the same region was more significantly found in the cribriform tumors than non-cribriform tumors (odds ratio: 2.64; 95% Conf. Interval: 1.02~6.59). Intriguingly, we only analyzed low DDB2 with high NRIP and high AR as a group, and low DDB2 with other three combinations as another group; and the p value of latter by Chi-square assay (odds ratio: 4.82; 95% Conf. Interval: 1.48~16.9) was more significant than the former. This indicates in case of low DDB2 in cribriform prostate cancer, NRIP and AR could be high expression. Hence NRIP protects AR in low DDB2 condition. As to in high DDB2, whether NRIP can protect AR from degradation by DDB2 in Cul4-DDB1 E3 ligase complex system remains unclear. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T12:33:16Z (GMT). No. of bitstreams: 1 ntu-105-R03445101-1.pdf: 5408890 bytes, checksum: aa95340ff6bd0e9f369edd0c46e31537 (MD5) Previous issue date: 2016 | en |
dc.description.tableofcontents | 口試委員審定書
中文摘要…………………………………………………….....…I Abstract……………………………....................……III Chapter 1 INTRODUCTION…………….......................1 1.1 Androgen receptor (AR) ........................……1 1.1.1The characteristics of AR…….............………1 1.1.2 The role of AR in prostate development ………….2 1.1.3 The role of AR in prostate cancer ……….....….2 1.2 Nuclear receptor interaction protein (NRIP).....….4 1.2.1 The characteristics of NRIP …................….4 1.2.2 The correlation of NRIP and AR in mouse prostate …5 1.3 DNA damage binding protein 2 (DDB2) …............…6 1.3.1The characteristics of DDB2 and cancer …...…6 1.3.2 The correlation between DDB2 and AR ….....8 1.4 The correlation of DDB2, NRIP, and AR……….……..9 1.5 Aim of this study...……................10 Chapter 2 MATERIALS AND METHODS…………..12 2.1 human samples sources…………………........…..12 2.2 Immunohistochemical assay (IHC).….........13 2.3 Quantification of protein expressions……….……14 2.4 Statistical analysis………………...…15 Chapter 3 RESULTS…………………….…16 3.1 The expression of NRIP protein in human prostate cancer..16 3.2 The expression of DDB2 protein in human prostate cancer.......17 3.3 The expression of AR protein in human prostate cancer....19 3.4 The relation between NRIP and DDB2 in prostate cancer.....20 3.5 The relation between AR and NRIP/DDB2 in prostate cancer.……….……........21 3.6 The correlation of NRIP, DDB2 and AR in prostate cancer................23 Chapter 4 DISCUSSION……………………25 Chapter 5 FIGURES……………….......33 Chapter 6 REFERENCES…………....…..47 | |
dc.language.iso | en | |
dc.title | 探討NRIP、DDB2和AR三者在攝護腺癌中的關係 | zh_TW |
dc.title | The correlation of NRIP, DDB2 and AR in prostate cancers | en |
dc.type | Thesis | |
dc.date.schoolyear | 104-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 楊宏志,李明學,黃祥博 | |
dc.subject.keyword | 核受體交互作用蛋白,雄激素受體,受損DNA結合蛋白2,攝護腺癌, | zh_TW |
dc.subject.keyword | NRIP,AR,DDB2,prostate cancers, | en |
dc.relation.page | 56 | |
dc.identifier.doi | 10.6342/NTU201601800 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2016-08-02 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-105-1.pdf 目前未授權公開取用 | 5.28 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。